Humedics Signs MOU with Almond&Co for AI-Based Aesthetic Device Business
Huons Group’s Humedics is making a strategic investment to enter the artificial intelligence (AI)-based non-invasive medical device and home beauty device markets.
On June 18, Humedics announced that it had recently signed a memorandum of understanding (MOU) for strategic investment and business collaboration with Almond&Co, a company specializing in the development of non-invasive beauty devices.
Kang Minjong, CEO of Humedics (left), and Seo Minjae, CEO of Almond & Co (right), are taking a commemorative photo after signing a business agreement at the Huons Group headquarters in Seongnam, Gyeonggi Province. Humedics
View original imageThis agreement has been arranged to jointly pursue the development of non-invasive medical devices by combining Almond&Co’s non-invasive drug delivery technology with Humedics’ expertise in the aesthetics business.
Through the agreement, the two companies will establish a cooperative framework for the non-invasive device business and work together on developing and commercializing new business models in aesthetic medicine. Humedics has secured exclusive domestic and overseas business rights for Almond&Co’s non-invasive medical devices and has obtained the right of first negotiation for home beauty devices. They expect to expand the scope of cooperation in the future based on the results of business feasibility reviews.
Almond&Co possesses technology for delivering active ingredients via non-invasive procedures that do not use needles. By combining skin measurement technology using contact electrodes with actuators and electronic control technology, they can precisely control drug delivery pressure and depth. Leveraging this technology, the company is developing both medical devices and home beauty equipment that deliver active ingredients more safely and effectively.
Humedics believes Almond&Co’s AI-based needle-free non-invasive drug delivery technology will evolve into a next-generation platform that reduces patient pain while enhancing the efficiency of active ingredient delivery. The company aims to use this platform to introduce a new paradigm to the medical aesthetics market, including skin boosters and botulinum toxin products.
Humedics plans to use this strategic investment to strengthen collaboration between the two companies and to consider developing differentiated product and service offerings by combining their capabilities.
Kang Minjong, CEO of Humedics, said, “By utilizing AI-based skin diagnosis technology, we plan to develop data-driven treatment protocols and expand our product portfolio in the future. Having already secured competitiveness in the invasive aesthetics market through ‘Dermashine,’ we will broaden our business scope to both invasive and non-invasive sectors through collaboration with Almond&Co.”
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Seo Minjae, CEO of Almond&Co, stated, “We are grateful for the strategic investment and partnership with Humedics, a leading aesthetics company in Korea. We hope this partnership will not only support Humedics’ leap as a global healthcare company but also contribute to Almond&Co’s continued future growth.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.